Avanos Medical, Inc. (AVNS)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$24.99+0.04%
Close 2026-07-24 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
Warn: Primary pillar under pressure — Cash flow from operating activities: OCF -12.3M vs target >0.
Avanos grew sales 8.8% in 2026-Q1. Specialty Nutrition sales rose 22.7%. The company is on track to complete a $1.27 billion acquisition. This deal could help future growth.
Cash flow dropped sharply in 2026-Q1, turning negative $16.6 million. Total operating income fell slightly. These show risks to profit and cash health.
The price is about 9% above our fair value near $23. Analysts expect about 2% revenue growth. We see some upside from the acquisition and specialty segment growth.
Breaks if: Acquisition fails to close by end of 2026
Finalize the acquisition transaction with American Industrial Partners to become a private company and leverage their operational expertise for growth.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
AVNS represents a turnaround investment, currently in a state of transition following its acquisition by American Industrial Partners. The company has shown strong revenue growth, but profitability improvements are mixed, indicating volatility in management execution.
The market appears to have priced in a stretched valuation, reflecting a low fragility tier amid a turbulent sector backdrop. Expectations are somewhat aligned with peers, but there is a notable gap in anticipated performance.
Recent financial performance has been strong, with revenue growth driven by the Specialty Nutrition Systems segment. However, operating income has seen a decline overall, suggesting that while growth is present, profitability remains a concern.
The future performance of AVNS hinges on management's ability to maintain revenue growth and improve operating income. Additionally, external factors such as sector performance and economic conditions, particularly job growth, will significantly influence the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 4 disclosures including 2026-Q1 and 2026-Q2. The acquisition was completed in 2026-Q2 at a valuation of approximately $1.272 billion with $25.00 per share paid to stockholders. Management consistently emphasized closing the transaction and transitioning to a private company, delivering on this priority.
“American Industrial Partners completes acquisition of Avanos Medical, Inc.”
“On April 14, 2026, announced the execution of a definitive agreement to be acquired by American Industrial Partners.”
“Avanos intends to nominate new directors and entered into cooperation agreement related to acquisition.”
Breaks if: Cash flow remains negative over next 4 quarters
Improve cash generation and free cash flow to support operations and strategic initiatives.
Stated in 2 quarters including 2026-Q1 and 2025-Q4. Cash from operating activities declined sharply from $25.7 million in 2025-Q1 to a use of $12.3 million in 2026-Q1, with free cash flow turning negative $16.6 million. Management's focus on cash flow shows limited progress with a deteriorating cash generation trend.
“Cash used in operations was $12.3 million, compared to cash flow from operations of $25.7 million a year ago.”
“Management focused on improving cash flow and liquidity.”
Breaks if: Operating income growth in segment falls below 5% next year
Enhance profitability through operational efficiencies and segment performance improvements, especially in Specialty Nutrition Systems.
Stated in 2 quarters including 2026-Q1 and 2025-Q4. Operating income declined from $10.3 million in 2025-Q1 to $8.9 million in 2026-Q1, but Specialty Nutrition Systems segment operating income grew 9.5% to $23.1 million. Management's focus on improving profitability shows mixed results with segment gains offset by overall decline.
“Operating income was $8.9 million, compared to $10.3 million a year ago.”
“Management focused on improving operating income and adjusted EBITDA.”
Breaks if: YoY revenue growth falls below 15% in Specialty Nutrition segment next year
Drive organic revenue growth, particularly in the Specialty Nutrition Systems segment, to build on momentum and expand market presence.
Stated in 2 quarters including 2026-Q1 and 2025-Q4. Revenue grew from $167.5 million in 2025-Q1 to $182.2 million in 2026-Q1 (+8.8%), driven by 22.7% growth in Specialty Nutrition Systems segment. Management's focus on revenue growth is delivering with solid organic expansion.
“Delivered double-digit organic growth led by Specialty Nutrition Systems segment.”
“Management focused on growth and strategic priorities for long-term success.”
Breaks if: YoY total revenue growth falls below 2% next year
Drive organic revenue growth, particularly in the Specialty Nutrition Systems segment, to build on momentum and expand market presence.
Stated in 2 quarters including 2026-Q1 and 2025-Q4. Revenue grew from $167.5 million in 2025-Q1 to $182.2 million in 2026-Q1 (+8.8%), driven by 22.7% growth in Specialty Nutrition Systems segment. Management's focus on revenue growth is delivering with solid organic expansion.
“Delivered double-digit organic growth led by Specialty Nutrition Systems segment.”
“Management focused on growth and strategic priorities for long-term success.”
In the next 1 to 3 years, AVNS's performance will depend on both internal execution and external market conditions. Not investment advice.